A new traffic fine warning has been issued by the Abu Dhabi Police
There's a fresh campaign rolled out across 73 advertising screens at Adnoc petrol stations across Abu Dhabi, Al Ain and Al Dhafra. The Abu Dhabi Police are encouraging drivers to act fast on outstanding fines through their 'Act Now and Benefit' initiative. The main headline? A 35 percent discount for those who pay up within 60 days.
Drive now, pay less
Got a fine? You now have options. If you settle it within two months of the violation, you'll get a 35 percent discount – no paperwork, no fuss.
Missed the deadline? You can still score a 25 percent discount if you pay within a year. These incentives apply to most violations, excluding the most serious offences.
It's a practical move designed to keep your wallet happy – and keep your driving record clean.
Fewer queues, smarter payment
Gone are the days of standing in line or rushing to meet office hours.
The Abu Dhabi Police have introduced flexible payment channels that include digital platforms, debit payment options and even instalment plans. Whether you're at home or on the go, you can now settle your fines on your terms.
Safety meets convenience
This isn't just about saving money – it's about safer roads and smarter systems. By broadcasting reminders at petrol stations, the initiative meets motorists where they are, using everyday stops as moments to encourage better habits.
The bottom line is, don't wait until the fine piles up. With discounts, digital tools and flexible plans now in place, there's no excuse to leave that penalty hanging. Check your traffic fines, act early and steer clear of unnecessary costs.
Abu Dhabi Police are making it easier than ever to drive responsibly – and affordably.
Summer in Abu Dhabi
The 27 best things to do indoors this summer in Abu Dhabi
It's time for some air-conditioned bliss
Psst: This is when summer officially ends in Abu Dhabi
No complaints here
25 brilliant beach and pool day passes in Abu Dhabi
Grab your SPF – a lush day by the water awaits
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
19 minutes ago
- Zawya
Bora Pharmaceuticals 2Q25 Operating Margin Expanded 5 Percentage Points, Reaching Quarterly High Since The Start of Integration in 4Q24; Strong Momentum Poised to Accelerate in 2H25 As Operational Efficiency Gains Materialize
HONG KONG SAR - Media OutReach Newswire - 8 August 2025 - Bora Pharmaceuticals (TWSE: 6472) today announced its financial results and operational highlights for second quarter of 2025. Quarterly Business and Financial Highlights · Company reported quarterly basic EPS of NT$5.95, with NT$1.81 from discontinued operations. OPEX was ~15% below guidance, aided by a ~4% FX gain. Gross margin was impacted by ~4% due to lower CDMO utilization. · FX loss totaled at ~NT$252 million in 2Q25, or NT$2.4 per share; Excluding FX impact from operational to non-OP, core EPS would have reached approximately NT$8.08, second highest on record after 1Q23, excluding all M&A related non-operating gains. · Fueled by expanded capacity and new dosage forms, Bora's CDMO business in 1H25, including internal orders, grew 69.5% compared to same period last year, reaching more than NT$5.01 billion, and yet posted a 26.6% sequential decline during the quarter due to slower momentum navigating through transitional integration phase mainly at sterile injectable site in Maryland and Zhunan facility with no impact on long-term fundamentals. · Pharma Sales revenues in 1H25 rose 23.0% YoY based on reported unaudited monthly sales, driven by market share expansion of the vigabatrin franchise across three dosage forms. VIGAFYDE uptake continued its acceleration during the quarter, supporting momentum into 2H25. · The Group observed robust CDMO order momentum in 3Q25, supported by a more streamlined and disciplined operating structure. With this solid execution base in place, Bora is confident that core profitability will resume. As CDMO growth accelerates through expanded U.S.-based capacity and capabilities in the near future, Bora shall be positioned for the next inflection point. · Share capital increased 0.25% during the quarter from employee stock option exercises and convertible bond conversions. Company went ex-rights on August 4 with book closure and record date both on August 10. · The Board approved setting up Bora Global Ltd., a wholly owned BVI subsidiary of Bora, and the injection of US$40mn in eye of fluctuating FX and other geo political nuances to reduce the Company's USD exposure. Mr. Bobby Sheng, Chairman of Bora Group, stated, "The second quarter marks our transition out of the integration phase that began in 4Q24 with stronger operational cash inflow. To further enhance our resilience to geopolitical and currency fluctuations, we have confirmed the establishment of Bora Global Ltd., a wholly owned BVI subsidiary. The planned injection of US$40 million into this entity reflects a proactive step to reduce the Company's USD exposure and strengthen financial flexibility amid ongoing macro uncertainties. Following multiple business and capacity acquisitions last year, we are proud to have established a solid foundation for operational efficiency gains and scalable growth in our change-enabling CDMO business and service-model oriented specialty pharma expansion. Looking ahead, Bora will advance its focus on high-value and complex dosage forms supported by ample cash on hand to grow our CDMO business. As of 2Q25, around 80% of our 2025 CAPEX plan has been deployed. One of the key investments include a high-performance filling line at our Canada site in Mississauga which enables larger volumes at higher speeds with greater flexibility, particularly for dermatologic products. The investment comes as the global dermatology drugs market is projected to nearly double in value to over $70 billion by 2030, reflecting the rising demand for high-quality, specialized treatments. In addition, while Flex-Pro line at our sterile injectable site in Maryland is expected to enter commercial stage production in 3Q25, while state-of-the-art isolated fill-finish system of automated vial, syringe, and cartridge filling line for the cGMP multi-product production of potent and targeted parenteral pharmaceuticals will take place over the course of 2026. Last but not least, year-to-date, we've added 8 new clients to our CDMO network, mostly for Maple Grove site in Minnesota. Newly added order backlog in 2025 increased to US$138 million. Majority of the contracts, in value, belongs to Canadian site and sterile injectable facility with orders from anchor new clients. On pharma sales side, specialty pharma business significantly outperformed expectations, with the vigabatrin franchise achieving double digit growth in market share. In the second half of the year, we plan to continue investing in channel marketing and strengthening engagement with key stakeholders on the payer side. The revenue mix between specialty pharma and generics reached 35% vs. 65% during the quarter, marking Bora's official transition into a specialty pharma company. Moving forward, we will focus on strengthening our presence in Ready-to-Use forms of dosages in the rare and underserved DEE (Developmental and Epileptic Encephalopathies) space through both in-licensing and proprietary R&D, enabling more efficient resource allocation and return in a market where me-too products have been under increasing pressure. This is part of Bora's ongoing transformation toward a more white-glove, service-oriented model across both pharma sales and CDMO, sharpening our strategic focus on high-demand, value-driven markets to scale, integrate, and synergize" 2Q2025 Operational Achievements & Full Year Outlook Global CDMO Operations Global CDMO Operations (excluding internal orders) revenues arrived at NT$1.59 billion in the second quarter, up 14.8% YoY and representing approximately 32.7% of total revenue. Including internal orders, CDMO revenue reached NT$5.01 billion. A total of 548 million doses were developed and manufactured. Revenue contribution from global top 20 pharmaceutical companies remained steady at approximately 32%. Bora continues to execute on expanding this customer base to enhance business visibility and stability. · In 1H25, the small molecule and sterile CDMO pipeline added US$138 million in backlog, marking historic high. · While the Company ramps up its Maple Grove site, it is seeing encouraging momentum - clinical-stage clients are transitioning to long-term strategic partnerships. In parallel, Bora observes a steady uptick in contract signings from pharmaceutical companies looking to secure US domestic manufacturing. Discussions remain active with potential anchor clients and the Company is planning the initiation of small molecule packaging line build-out as the first step in our capacity pre-sell strategy. · Large molecule CDMO operation was launched following the January 20 reverse-acquisition of Bora Biologics by Tanvex Biopharm where Bora owns 30.5% of Tanvex. CDMO operations at the San Diego site are now active, and the ongoing 2,000L expansion has received strong interest from late-stage clients with half of the potential deals from US clients. Pharma Sales Operations Pharma Sales Operations revenue reached NT$3.26 billion, down 10.4% YoY, primarily due to discontinuing several products under significant pricing pressure. Pharma Sales accounted for approximately 67.0% of total revenues. · Bora identified a shift from DRE (Drug Resistant Epilepsy) to DEE (Developmental and Epileptic Encephalopathies) in the epilepsy market since the acquisition of Upsher-Smith and validated, through field work of sales and marketing, that legacy compounds fall short in addressing the significant unmet needs in this segment. Approved treatments were only available for epilepsies related to Dravet Syndrome, Lennox-Gastaut Syndrome, TSC (Tuberous Sclerosis Complex) and CDKL5 deficiency at the moment, meaning more NCEs will come in the near future, further enlarging the addressable market. The Company expects to capture the sizable opportunities of approximately US$ 10 billion in the next 3 to 5 years building a sound pipeline with Ready-to-Use 505(b)(2) such as Stiripentol, USL551, and at least 2 more compounds. Bora continues to await regulatory approval for 3 high-value generics in our pipeline in the remainder of the year. Recent Investor Conference Bora will host an English online earnings call at 6:00 p.m. Taiwan time on Aug. 8, 2025, followed by an investor conference hosted by Taishin Securities at the Grand Hyatt Taipei at 2:30 p.m. on Aug. 12, 2025. Both events will cover the company's Q2'25 financial and business results and outlook. 🔗 English Online Earnings Presentation Link: Bora will participate in the Daiwa Consumer and Healthcare Conference on Sept. 3-4 in Hong Kong and Goldman Sachs CDMO Day on Sept. 16-17 in Singapore. For 1:1 meetings with management, please contact your Daiwan and Goldman Sachs representative. Bora 2025 Earnings Schedule Q3 2025: Expected in the 3 rd week of November 2025 Q4 2025: Expected in the 2 nd week of March 2026 Hashtag: #BoraPharmaceuticals The issuer is solely responsible for the content of this announcement. About Bora: Founded in 2007, Bora Pharmaceuticals ("Bora" or "the Company", is a leading pharmaceutical services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life. By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. For more information, please visit: Disclaimer: This document and the accompanying information may contain forward-looking statements. All statements regarding the company's future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company's control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates. Bora Pharmaceuticals
Zawya
19 minutes ago
- Zawya
Trump's Fed shake-up sends Wall St futures higher on rate easing hopes
U.S. stock index futures rose on Friday after President Donald Trump's temporary pick for a Federal Reserve governor fueled expectations of a more dovish policy ahead. At 6:52 a.m. ET, S&P 500 E-minis were up 19.5 points, or 0.31%, Nasdaq 100 E-minis were up 74.5 points, or 0.32%, and Dow E-minis were up 107 points, or 0.24%. Investors were being whipsawed by mixed signals over the Fed's future, as Trump's pressure stirs worries about the central bank's independence and a potential leadership reshuffle that could skew policy looser. On Thursday, the U.S. president said he will nominate Council of Economic Advisers chair Stephen Miran for a short-term Fed seat while the White House hunts for a permanent governor and a new chair. Miran replaces Governor Adriana Kugler following her surprise resignation last week. The S&P 500 and the Dow cooled in the last session after Bloomberg News reported Fed Governor Christopher Waller was emerging as a leading contender for the chair. "He's (Miran) widely expected to join Waller and Michelle Bowman in the dovish camp for the few meetings he will attend, with a non-negligible risk he might try to build consensus for a 50 basis point move," ING analysts send in a note. The Nasdaq and the S&P 500 were on track for their best week in over a month, buoyed by tech names after signs they could sidestep new chip tariffs by building more in the United States. Apart from tech stocks, equities have ridden a sharp reset in rate expectations and a flurry of upbeat earnings. The CME FedWatch tool shows traders see a 90% chance of the first rate cut of the year coming next month - and futures point to at least two cuts by year-end. On Thursday, the S&P 500 and the Dow ended lower, weighed down by a 14.1% drop in Eli Lilly after results from a late-stage study on its experimental GLP-1 pill fell behind that of Novo Nordisk's. Sector-wise, consumer discretionary could top the leaderboard this week, while healthcare lags, weighed down mainly by Eli Lilly. Meanwhile, U.S. tariffs on a bunch of trading partners took effect at midnight on Thursday. Tokyo's trade negotiator said Washington will amend a presidential executive order to remove overlapping tariffs on Japanese goods, terming it as oversight. In earnings-related moves, Trade Desk sank 30% in premarket trading after the ad-tech firm reported a sharp slowdown in second-quarter revenue growth. Pinterest tumbled 11% as the social media platform missed analysts' estimates for second-quarter profit. Microchip Technology lost 7.9% after the chipmaker's first-quarter results failed to impress investors. St. Louis Fed President Alberto Musalem is scheduled to speak later at 10:20 a.m. ET. (Reporting by Nikhil Sharma and Pranav Kashyap in Bengaluru; Editing by Maju Samuel)
Khaleej Times
19 minutes ago
- Khaleej Times
Traffic alert: Dubai Police warn of accident in DWTC tunnel
Dubai Police have sent out a warning about a disruption in traffic flow on Friday due to an accident in Dubai World Trade Centre tunnel (DWTC) towards Sharjah. The police urged motorists to exercise caution and care while approaching the area.
